Stockscreener 앱 받기
1.04
1.89%
-0.02
시간 외 거래:
1.06
0.02
+1.92%
Pyxis Oncology Inc 주식(PYXS)의 최신 뉴스
Statistical indicators supporting Pyxis Oncology Inc.’s strengthSafe Entry Strategy with High Win Rate - Newser
Visual analytics tools that track Pyxis Oncology Inc. performanceQuarterly Investment Outlook and Key Summary - Newser
Can Pyxis Oncology Inc. recover in the next quarterFree Growth Based Stock Signal Screener - Newser
Pyxis Oncology Inc. stock prediction for this weekShort-Term Trade Setup with Forecast Insight - Newser
Pyxis Oncology Inc. stock chart pattern explainedTrend Confirmation Scanner with Entry Focus - Newser
Pyxis Oncology PYXS 2025Q2 Earnings Preview Downside Concerns Amid Revenue Uncertainty - AInvest
Why Pyxis Oncology Inc. stock attracts strong analyst attentionFree Triple Digit Growth Focused Trade Plan - Newser
Will Pyxis Oncology Inc. outperform the marketFree Real Trader Watchlist of Hot Stocks - Newser
Real time scanner hits for Pyxis Oncology Inc. explainedBuy Strategy Review With Performance Summary - Newser
Earnings visualization tools for Pyxis Oncology Inc.Daily Technical Forecast for Quick Gains - Newser
AI Trend Models Suggest Bounce for Pyxis Oncology Inc.Early Entry Picks Before News Breakout Reviewed - beatles.ru
Custom strategy builders for tracking Pyxis Oncology Inc.Trading Opportunities Forecast by AI Insight - Newser
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.00 Consensus Price Target from Analysts - Defense World
How Pyxis Oncology Inc. stock performs during market volatilityGrowth Projection Summary for Long-Term Investors - Newser
Should you hold or exit Pyxis Oncology Inc. nowPrice Spike Prediction for Active Traders - Newser
Pyxis Oncology shares rise 4.36% after-hours after announcing revisions to patient enrollment for Phase 1 clinical trial. - AInvest
Pyxis Oncology Updates Phase 1 Trial Enrollment: What You Need to Know - AInvest
Pyxis Oncology updates patient enrollment for Phase 1 trial of micvotabart pelidotin - Investing.com
Pyxis Oncology Updates Phase 1 Trial Enrollment - TipRanks
How to integrate Pyxis Oncology Inc. into portfolio analysis toolsImmediate Entry Point Prediction Strategy - Newser
How does Pyxis Oncology Inc. compare to its industry peersBreakthrough capital growth - Jammu Links News
What are analysts’ price targets for Pyxis Oncology Inc. in the next 12 monthsBreakthrough capital growth - Jammu Links News
What are the technical indicators suggesting about Pyxis Oncology Inc.Unlock daily trading alerts for profits - Jammu Links News
Should I hold or sell Pyxis Oncology Inc. stock in 2025Outstanding capital returns - Jammu Links News
What makes Pyxis Oncology Inc. stock price move sharplyDynamic profit opportunities - Jammu Links News
Pyxis Oncology Inc. Stock Analysis and ForecastBuild capital through low-risk investments - Jammu Links News
What institutional investors are buying Pyxis Oncology Inc. stockFastest return on investment - Jammu Links News
What is Pyxis Oncology Inc. company’s growth strategyInvest smarter with expert stock picks - Jammu Links News
We Think Pyxis Oncology (NASDAQ:PYXS) Needs To Drive Business Growth Carefully - uk.finance.yahoo.com
Pyxis Oncology Inc. Consolidation Zone May Signal AccumulationLow Capital High Return Stock Plans Reviewed - metal.it
What high frequency data says about Pyxis Oncology Inc.Weekly Watchlist of High Movers Released - metal.it
Live Scanner Shows Breakout on Pyxis Oncology Inc.Stock Selection With High Accuracy Based on Models - metal.it
Risk adjusted return profile for Pyxis Oncology Inc. analyzedSmart Trade Forecast Based on Neural Logic - Newser
Bullish Candlestick Pattern Forms in Pyxis Oncology Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
Chartists See Breakout Potential in Pyxis Oncology Inc.Growth Focused Entry Plan Suggestions Issued - metal.it
How did PYXS's revenue and expenses trend in Q4 2024? - AInvest
Price action breakdown for Pyxis Oncology Inc.Stable Entry High Return Opportunities in Focus - metal.it
1.02%
3.70%
자본화:
|
볼륨(24시간):